HealthcareServices

GM1 Gangliosidosis Market Outlook: Growth and Forecast Highlights 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gm1 gangliosidosis market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the GM1 Gangliosidosis Market between 2026 and 2030?

The gm1 gangliosidosis market has experienced substantial expansion in recent years. Its valuation is predicted to increase from $0.57 billion in 2025 to $0.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.1%. This historical growth can be attributed to elements such as rare disease research initiatives, the identification of enzyme deficiencies, progress in genetic diagnostics, hospital-based pediatric care, and early clinical studies.

The gm1 gangliosidosis market is set for significant expansion in the coming years. It is projected to reach $0.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period is driven by factors such as the development of gene therapy pipelines, incentives for orphan drugs, enhancements in diagnostic screening, increased patient advocacy, and expanded biotechnology funding. Prominent trends for this period include a heightened focus on rare disease drug development, more extensive research into gene therapy, increasing adoption of enzyme replacement therapies, the broadening of newborn genetic screening, and a surge in clinical trial activity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

Which Drivers Are Expected To Impact The GM1 Gangliosidosis Market During The Forecast Period?

The expanding use of gene therapy is projected to boost the GM1 gangliosidosis market’s expansion in the future. This medical approach entails modifying or substituting genes within an individual’s cells to either treat existing conditions or prevent their occurrence. Its rising uptake stems from progress in genetic research, better patient results for conditions that were previously without effective treatments, and increasing regulatory backing for novel therapeutic methods. Specifically for GM1 gangliosidosis, gene therapy entails introducing a working version of the impaired gene (GLB1) into a patient’s cells, aiming to re-establish ß-galactosidase enzyme function and decrease the accumulation of harmful substances. An example is that in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated a 10% rise in the count of gene therapies in Phase III during Q4 2023 relative to the preceding quarter. This marked the initial increase observed since Q3 2022. Consequently, the expanding use of gene therapy is propelling the growth of the GM1 gangliosidosis market.

Which Segments Are Driving Activity In The GM1 Gangliosidosis Market?

The gm1 gangliosidosis market covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

Which Competitive Trends Are Impacting The Structure Of The GM1 Gangliosidosis Market?

Companies operating in the GM1 gangliosidosis market are prioritizing strategic partnerships to maintain their market position. These alliances are critical for advancing gene therapy development by integrating expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. As an illustration, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, collaborated with the Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to create gene therapies for rare diseases, including GM1 gangliosidosis. This agreement includes up to $100 million in funding from Fiocruz for clinical research and manufacturing, with the aim of making these advanced therapies available through Brazil’s public healthcare system. The collaboration emphasizes technology transfer and seeks to democratize access to treatments that were formerly limited to higher-income populations.

Which Major Industry Participants Are Leading The GM1 Gangliosidosis Market Growth?

Major companies operating in the gm1 gangliosidosis market are Pfizer Inc, Sanofi S A, Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc, CRISPR Therapeutics AG, REGENXBIO Inc, Passage Bio Inc, Orchard Therapeutics plc, AVROBIO Inc, uniQure N V, Lysogene S A, Sio Gene Therapies Inc, bluebird bio Inc, Axovant Gene Therapies Ltd, Lysosomal Therapeutics Inc, Encoded Therapeutics Inc, Abeona Therapeutics Inc, JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2025. The regions covered in the gm1 gangliosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized GM1 Gangliosidosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Browse Through More Reports Similar to the Global GM1 Gangliosidosis Market 2026, By The Business Research Company

Glycol Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Alpha Mannosidosis Market 2026

https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market

Paraganglioma Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795